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Abstract
Background: Angiogenesis plays a pivotal role in malignant tumor progression. The count of blood microvessels of
the tumor has been recognized as an indicator of malignant potential of the tumors and provides the ability to
predict tumors recurrence. The role endoglin in the Dukes B rectal cancer is still unexplored. The aims of this study
were to examine immunohistochemical expression of endoglin in resected rectal cancer and investigate the
relationship of tumor recurrence and other clinicopathological variables to the endoglin-assessed microvessel
density of the tumor tissue and distal resection margins.
Methods: The study included 95 primary rectal adenocarcinomas, corresponding to 95 distal and 95 proximal
resection margin specimens from surgical resection samples. Tumor specimens were paraffin embedded, and
immunohistochemical staining for the CD105 endothelial antigen was performed to count CD105-MVD. For exact
measurement of the CD105-MVD used, a computer-integrated system Alphelys Spot Browser 2 was used.
Results: The MVD was significantly higher in the tumor samples compared with the distal resection margins (p <
0.0001) and the proximal resection margins (p < 0.0001). There was no significant difference in the MVD between
distal and proximal resection margins (p = 0.147). The type of surgical resection was a significant factor for
determining the recurrence of tumors (p = 0.0104). There was no significant effect of patients’ age, gender, tumor
location, grade of differentiation, histological tumor type, and the size and depth of tumor invasion on the
recurrence of the tumor. The recurrence rate was significantly higher in the low CD105-MVD group of patients than
in the high CD105-MVD group of patients (log rank test, p = 0.0406). Result of the multivariate analysis showed that
the type of surgery (p = 0.0086), MVD tumors (p = 0.0385), and MVD of proximal resection margin (p = 0.0218) were
the independent prognostic factors for the recurrent tumors.
Conclusions: CD105-assessed MVD could help to identify patients with more aggressive disease and increased risk
of developing tumor recurrence after surgical treatment in stage II rectal cancer (RC).
Keywords: Rectal cancer, Angiogenesis, Microvessel density, Endoglin, Recurrence
Background
Radical surgical treatment of stage II rectal cancer (RC)
is surgical challenge associated with high risk of recur-
rence of the tumor [1]. After total mesorectal excision
surgery with intent, despite the absence of nodal disease,
25 % of these patients will relapse within 5 years [2, 3].
Recurrence of the tumor is an adverse prognostic
indicator with a poor overall survival prognosis [4]. The
risk of relapse may be estimated by assessing the clinical
and histopathological features of the cancer [5].
Tumor growth and its spread to adjacent tissue de-
pend on its ability to stimulate angiogenesis. Angiogen-
esis consists of formation of new blood vessels from
pre-existing vasculature [6]. The studies have shown
that the angiogenic potential of a tumor may be in-
ferred from its vascularity measured in histological sec-
tion [7]. The count of blood microvessels of the tumor,
as shown in microvessel density (MVD), has been
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recognized as an indicator of malignant potential of the
tumors and provides the ability to predict tumor recur-
rence and survival. Endoglin (CD105) has been sug-
gested to be the most suitable marker available to
quantify tumor angiogenesis [8].
Our study aimed to examine immunohistochemical
expression of CD105 in stage II RC and to investigate a
correlation between CD105-assessed MVD and clinico-
pathological variables and to analyze prognostic value of
MVD on the tumor recurrence.
Methods
Patients and specimens
We studied 95 cases of primary rectal adenocarcinomas
in stage II (T3–T4, N0, M0) treated by complete surgical
resection (R0) in a 5-year period at Clinic for Surgery,
Clinical Hospital Center Rijeka, Croatia, from January
2002 to December 2006. The study included 95 primary
rectal adenocarcinomas, 95 surgical distal resection mar-
gin specimens, and 95 surgical proximal resection mar-
gin specimens from surgical resection samples. The
distal resection margin (DRM) and proximal resection
margin (PRM) corresponding to the primary tumor from
the same patients was taken from the margin of near
and distant surgical resection. Tissue samples included
in this study were retrieved from the archives of the
Institute of Pathology School of Medicine of Rijeka,
Croatia. The exclusion criteria were a synchronous
tumor or tumors in another localization in anamnesis,
emergency surgery, preoperative radiotherapy or chemo-
therapy, perforation of bowel, and incomplete clinical
data. The study was approved by the University of Rijeka
Ethics Committee and patients signed informed consent.
All of the patients underwent radical low anterior re-
section (LAR) or abdominoperineal resection (APR). All
patients had confirmed rectal adenocarcinomas by histo-
pathology and were staged according to the 7th edition
of the American Joint Committee on Cancer Staging
Manual [9]. The histological grading was classified ac-
cording to the World Health Organization (WHO) clas-
sification [10]. The mean duration of follow-up was
54.7 ± 23.1 months (median duration, 60.0 months)
after the operation for RC. Recurrence data and cause of
death of those who died during follow-up period were ob-
tained from the Croatian Cancer Registry. Patient and
tumor characteristics are presented in Table 1.
Immunohistochemistry
Immunohistochemical analysis was performed on
formalin-fixed paraffin-embedded section. All tissue
samples from RC, DRM, and PRM were fixed in 10 %
buffered formalin and embedded in paraffin. We pre-
pared 4-μm-thick serial section which were deparaffi-
nized in xylene, rehydrated in graded ethanol, and
washed with phosphate-buffered saline. Endogenous
peroxidase was inhibited with 3 % hydrogen peroxide.
Tissue sections were incubated for 30 min with the
anti-CD105 primary monoclonal antibody (mouse
anti-human, clone SN6h, Dako Corporation, Denmark)
at a 1:10 dilution. Primary antibody binding site was
visualized using a secondary antibody detection kit
(Envision + kit; Dako, Denmark).
The staining was visualized with diaminobenzidine
(DAB). Tissue sections were counterstained with
hematoxylin. Brown staining for CD105 was consid-
ered positive. Distant normal mucosa free of tumor
were used as positive controls, and the primary
Table 1 Clinical and pathologic characteristics of the rectal
cancer samples
Characteristics Number of patients
Total number 95
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antibody was replaced with phosphate-buffered saline
solution for negative controls.
Evaluation of staining and of MVD by computerized
image analysis
All slides stained with anti-CD105 were viewed and an-
alyzed with Alphelys Spot Browser 2 integrated system,
using a software controlled (Alphelys Spot Browser
2.4.4., France) stage positioning Nikon Eclipse 50i
microscope mounted 1360 × 1024 resolution Microvi-
sion CFW-1310C digital camera. The slides were
scanned at ×20 magnification to identify “hot spots”
(areas with the highest microvessel concentration) for
the slides and then ×200 magnification to create images
for quantification scoring positive cells and MVD. Posi-
tive cells were counted in the tumor, DRM, and PRM
and presented as percentage of positive cells and MVD
as number of microvessels in the histological field accord-
ing to Weidner et al. [11]. The regions with the most
intensive vascularization (hot spots) were defined by scan-
ning the entire tumor section at low magnification with a
selection of four fields. The areas of this histological field
was 0.612 mm2. Hot spots were identified by two inde-
pendent observers at ×20 magnification.
Statistical analysis
Statistical analysis was performed using MedCalc version
14.8.1 (MedCalc Software bvba, Mariakerke, Belgium).
Descriptive statistics and 95 % confidence intervals were
calculated to describe data. The distribution of data was
tested for normality using the Smirnov-Kolmogorov test.
The Mann-Whitney U test and Kruskal-Wallis tests
were used to compare MVD among the clinicopatholog-
ical variables. Spearman’s rho correlation was used to
test the correlation between the immunohistochemical
findings and tumor recurrence. The receiver operating
characteristic (ROC) curve approach was used to
determine best-fitting cut-off for the MVD in terms of
the tumor recurrence analysis [12]. Tumor recurrence
analysis was estimated by the Kaplan-Meier method and
compared by the log rank test. Prognostic factors of
tumor recurrence were identified by the use of the Cox




We assessed paraffin-embedded specimens from tumors
from the 95 patients resected for RC. Clinicopathological
characteristics of patients are summarized in Table 1.
The median age at diagnosis was 69 years (range 15 to
85 years), 49 patients (51.6 %) were ≤69 years of age,
and 46 patients (48.4 %) were >69 years old. Sixty-one
(64.2 %) were males and 34 (35.8 %) were females. In 23
patients (24.2 %), the tumor was located in the upper
rectum, in 52 (54.7 %), in the middle rectum and in 20
(21.1 %), in the low rectum. According to the grade of
differentiation, 55 patients (57.9 %) were G1 (well differ-
entiated), 34 (35.8 %) G2 (moderately differentiated),
and 6 (6.3 %) G3 (poorly differentiated). According to
the depth of tumor invasion, 37 patients (38.9 %) were
T3, 42 (44.2 %) T4a, and 16 (16.9 %) T4b. Eighty-two
(86.3 %) tumors were classified as adenocarcinomas and
13 (13.7 %) as adenocarcinomas with mucinous features.
Median tumor size was 3.8 cm (range, 1.3 to 12.0 cm).
The median patients follow-up was 60 months (range,
1.0 to 109.0 months). Of the 95 patients, 16 patients de-
veloped recurrence of the tumor (recurrence rate,
16.8 %) and 29 died of RC (overall survival rate, 30.5 %)
in the 5-year follow-up period.
Microvessel density
MVD were analyzed in tumors, distal resection margins,
and proximal resection margins. Examples of CD105
Fig. 1 Immunohistochemical staining for the CD105 endothelial antigen in the tumor samples (a), distal resection margins (b), and the proximal
resection margins (c). Magnification ×200
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expression in the tumor samples, distal resection mar-
gins, and the proximal resection margins are shown in
Fig. 1. Median CD105-assessed MVD in tumors was
174.47 vessels/mm2 (95 % CI 151.00–205.29), distal re-
section margins 89.86 vessels/mm2 (95 % CI 55.46–
103.80), and the proximal resection margins 58.82 ves-
sels/mm2 (95 % CI 51.42–82.56). The MVD was signifi-
cantly higher in the tumor samples compared with distal
resection margins (Wilcoxon test, p < 0.0001) and the
proximal resection margins (Wilcoxon test, p < 0.0001)
(Fig. 2). There was no significant difference in the
MVD between distal and proximal resection margins
(Wilcoxon test, p = 0.147). We found that CD105-MVD
in tumor tissue (rho = −0.321, p = 0.0015, 95 % CI −.491
to −1.128) and proximal resection margins (rho = −0.220,
p = 0.0324, 95 % CI −0.403 to −0.019) correlated inversely
with tumor recurrence rate. On the other hand,
CD105-MVD in distal resection margins (rho = 0.312,
p = 0.0021, 95 % CI 0.118 to 0.483) correlated posi-
tively with tumor recurrence rate. There was statisti-
cally significant correlation between CD105-MVD in
tumor (≤106.2 vessels/mm2/>106.2 vessels/mm2)
(Fig. 3a; p = 0.0037), CD105-MVD in DRM (≤186.3
vessels/mm2/>186.3 vessels/mm2 (Fig. 3b; p = 0.0076),
CD105-MVD in PRM (≤27.8 vessels/mm2/>27.8 ves-
sels/mm2) (Fig. 3c; p = 0.0490), and tumor recurrence
as determined by Fisher’s exact test.
Univariate recurrence analysis
The Kaplan-Meier method and log-rank test were per-
formed. In the univariate analysis (Table 2), the type of
surgical resection was a significant factor for determin-
ing the recurrence of tumors (log-rank test, p = 0.0104)
(Fig. 4). There was no significant effect of patients’ age,
gender, tumor location, grade of differentiation, histo-
logical tumor type, the size and depth of tumor invasion
on the recurrence of the tumor.
The cut-off value for determining high and low MVD
with respect to recurrent tumor was performed by the
receiver operating characteristic (ROC) curve analysis.
The cut-off value for MVD in tumors, distal and prox-
imal resection margins were ≤106.2 microvessel/mm2
(sensitivity 56.2 %, specificity 81.0 %), >186.3 micro-
vessel/mm2 (sensitivity 37.5 %, specificity 91.1 %),
and ≤27.8 (sensitivity 43.7 %, specificity 81.0 %), re-
spectively (Table 3). The cut-off values for MVD in
the primary tumors, distal resection margins, and
proximal resection margins are shown in Fig. 5.
In a Kaplan-Meier recurrence of tumors estimate
(Table 4), tumor with a low MVD (Fig. 6a, log-rank
test, p = 0.0008) and tumor with low MVD proximal re-
section margin (Fig. 6b, log-rank test, p = 0.0074) had
significantly higher risk of developing recurrence. The
risk of developing recurrence was significantly higher in
the group of patients with high MVD distal resection
Fig. 2 Box-and-whisker plots of CD105-MVD in tumors, distal resection margins, and proximal resection margins. The CD105-MVD level was
significantly higher in the tumor compared with the distal resection margin (p < 0.001) and the proximal resection margin (p < 0.001). In these
box plots, median values are represented by lines within the boxes, whiskers represent the interquartile range, and outliers are represented as
individual data points
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Fig. 3 Correlation analysis between tumor recurrence and CD105-MVD in tumor, distal and proximal resection margin. a Recurrence and CD105-
MVD in tumor (p = 0.0037). b Recurrence and CD105-MVD in DRM (p = 0.0076). c Recurrence and CD105-MVD in PRM (p = 0.0490)
Table 2 Univariate analysis for tumor recurrence







Type of surgery 0.010
Low anterior resection 1.000
Abdominoperineal resection 3.140 0.919–10.725
Tumor location 0.710
Upper rectum 1.000
Middle rectum 1.267 0.381–4.213
Low rectum 1.716 0.419–7.026






Adenocarcinoma with mucinous features 0.381 0.096–1.514






>4 cm 0.594 0.214–1.651
95 % CI confidence interval
*log-rank test
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margin compared with low MVD distal resection mar-
gin (Fig. 6c, log-rank test, p = 0.0211).
Multiple Cox regression analysis
The prognostic variables were determined by Cox pro-
portional hazard regression analysis. The variables: age,
gender, type of surgical resection, tumor location, grade
of differentiation, histological type, depth of tumor inva-
sion, tumor size, length of the surgical distal and prox-
imal margin, MVD tumors, and MVD of surgical distal
and proximal margin were entered into the multivariate
model to determine their relation with recurrent tumors.
“Backward” analysis was performed. Results of the multi-
variate analysis are presented in Table 5. The result
showed that the type surgery (OR = 4.11, p = 0.0086),
MVD tumors (OR = 0.33, p = 0.0385), and MVD of prox-
imal resection margin (OR = 0.27, p = 0.0218) were the
independent prognostic factors for recurrent tumors.
Tumor size and MVD distal resection margins were on
the border of significance.
Discussion
Stage II RC is defined by the presence of penetration
through the muscularis propria and the absence of me-
tastasis to either regional lymph nodes or distant sites
[13]. Rectal cancer surgery is effective for localized dis-
ease; however, approximately 25–30 % patients with
stage II disease are at high risk for postoperative recur-
rence, and the clinical outcome of these patients is simi-
lar to that of patients with stage III disease [14].
Identifying high-risk patients with stage II RC is import-
ant because it may help to identify patients and add-
itional risk for whom surgery alone may not be a
curative treatment. During the past two decades, many
clinicopathologic studies indicate the importance of
tumor angiogenic activity in defining the aggressiveness
of tumor behavior [15]. The microvessel density (MVD),
which is based on the morphological visualization and
quantification of blood vessels, represents a possible
prognostic value in colorectal cancer [16]. Over the past
decade, numerous studies have investigated the value of
angiogenesis markers in CRC. Endoglin is a proliferation-
associated antigen on endothelial cells and essential for
angiogenesis. It has been reported that expression of the
endoglin in tumor endothelium may be a prognostic in-
dicator of the outcome for various human tumors
including and colorectal cancer (CRC) [17]. Many
angiogenesis markers have been studied but have not
been used in conjunction with the angiogenesis in the
surgical resection margins.
Microvessel density assessment is the most commonly
used technique to quantify intra-tumoral angiogenesis in
Fig. 4 Kaplan-Meier curves for recurrence-free survival according to the type of surgery. Solid line, patients with LAR. Dotted line, patients with APR
Table 3 Optimal cut-off point of CD105-MVD in tumors, distal
resection margins, and proximal resection margins
Variables AUC Cut-off value Sensitivity Specificity
MVD in tumors 0.601 106.2 56.2 81.0
MVD in DRM 0.656 186.3 37.5 91.1
MVD in PRM 0.602 27.8 43.7 81.0
AUC area under the curve
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cancer. In the present study, we assessed MVD with
CD105 marker in RC tissue, distal resection margin, and
proximal resection margin. In our cohort, endoglin
microvessel immunostaining was consistently present in
all the cases studied. We showed that the CD105-MVD
values significantly increase in RC from the proximal
and distal resection margin to the primary tumor (Fig. 2).
These results support the role of CD105 as an optimal
marker of proliferation of endothelial cells and its poten-
tial as prognostic factor [13, 14, 18]. In our study, overall
5-year recurrence rate for all patients included in this
study was 16.8 %.
Recurrence rates in our cohort stage II RC patients
were analyzed according to age, gender, surgery, tumor
location, grade of differentiation, histology, depth of
tumor invasion, and tumor size (Table 2). By univariate
analysis, only the type of surgical resection was found to
be significant prognostic factors for tumor recurrence.
Patients treated with a primary APR had a higher rate of
tumor recurrence than those who underwent a LAR,
which is in accordance with the results of most of the
authors [19]. Previous studies have demonstrated an
LAR to APR ratio 3:1 or 4:1 which is consistent with our
results [19, 20]. However, most studies were too small to
adequately evaluate the relationship between the type
surgery and tumor recurrence (TR). The key to success-
ful surgery is complete excision of the tumor with suffi-
cient margin of normal tissue. TR may also sometimes
occur even in the absence of an involved CRM possibly
owing to lymphatic spread from the distal rectum to
lymph nodes in the pelvic side wall [21]. In low rectal
cancer, total mesorectal excision (TME) surgery may be
insufficient to obtain the desired CRM because of lack
of mesorectum at the level of the pelvic floor [22]. APR
surgery frequently results in perineal and presacral TR
[23]. The choice of surgical resection is limited and in-
fluenced by tumor staging, tumor location, and intrapel-
vic tumor invasion at the time of the diagnosis [24].
Patients with stage II RC have a high risk of develop-
ing recurrence of the tumor despite multimodality treat-
ment [25]. Although angiogenesis affect the outcome of
treatments, the importance of angiogenesis as a prog-
nostic factor is still not clearly enough defined. In the
studies, there are considerable differences in microvessel
counts in tissue of rectal carcinoma. The quantification
of microvessel density was made in the majority of stud-
ies with classical Weidner’s method [11]. In our study,
tumor microvessel density was obtained by computer-
ized image analysis.
For colorectal cancer, conflicting results have been re-
ported on the prognostic importance of MVD in predic-
tion of tumor aggressive behavior in various subsets of
patients. Due to inconsistent methods of analysis of
tumor angiogenesis in various studies, it is difficult to
compare the values of MVD obtained in our analysis
with the results of other authors. In our analysis, we
found higher values of MVD (CD105-MVD, 221.0/mm2
on average) in RC tissues in comparison with the results
in the study of Svagzdys et al. (CD34-MVD, 193.0/mm2
on average), possibly due to the larger surface of the an-
alyzed tumor tissue (0.612 versus 0.576/mm2) and the
use of different endothelial cell markers [26]. In the
Fig. 5 Receiver operating characteristic (ROC) curve analysis for optimal cut-off point of CD105-MVD. a Cut-off value of MVD in tumor 106.2/mm2.
b Cut-off value of MVD in DRM 186.3/mm2. c Cut-off value of MVD in PRM 27.8/mm2
Table 4 The recurrence rates and univariate analysis according
to cut-off values for MVD





MVD in tumors 0.0008
≤106.2 24 37.5
>106.2 71 9.8
MVD in DRM 0.0074
≤186.3 82 12.2
>186.3 13 46.1
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present study, the microvessel counts are high and con-
firm that the rectal carcinoma is strongly dependent on
angiogenesis.
Furthermore, significantly higher rates of tumor recur-
rence were found in patients with lower MVD in tumors
than in cut-off value obtained by ROC analysis. This is
shown by Kaplan-Meier recurrence curve for MVD in
RC tissue (Fig. 5). Our results suggest that the lower
CD105-MVD is accompanied by higher rate of tumor
recurrence, which is not in accordance with the results
that an increased CD105-MVD was correlated with re-
currence of the disease after radical resection. In their
study, Skoufi et al. have found a strong association be-
tween increased CD105-MVD and recurrence of CRC
[27]. Chen et al. have reported that the RC with higher
MVD are more likely to recur or metastasize after rad-
ical resection (CD31 immunostaining, average as cut-
off ) [28]. Other studies demonstrated that high MVD
counts determined using CD105 were strongly associ-
ated with high risk of metastatic disease (Saad et al.,
Romani et al., median as cut-off ) [29, 30]. According to
the results in the study of Uribarrena et al., patients with
stage I and II colorectal carcinomas with higher vascular-
ized tumor area had a significant association with a better
outcome, but no significant relationship was observed be-
tween MVD and tumor recurrence and death [31]. Some
studies reveal that MVD determined with CD105 is not
correlated with recurrence rate [32, 33].
In the present study, we found a significant inverse
correlation between the CD105-MVD in the distal resec-
tion margins and the length of DRM that were closest to
the RC. This analysis suggested an active reaction of the
adjacent mucosa related to the presence of the tumor,
but a more passive reaction induced by the factors re-
leased from the tumor [34]. Also, our result shows a
significant correlation between the CD105-MVD and
tumor recurrence: significantly higher rates of tumor
recurrence were found in patients with higher CD105-
MVD in distal resection margins than cut-off value ob-
tained by ROC analysis. Regarding the pattern of recur-
rence after surgery alone, we revealed that lower
CD105-MVD in tumors and higher CD105-MVD in
distal resection margins significantly correlated with
tumor recurrence, suggesting that CD105 may be in-
volved in developing tumor recurrence in rectal cancer.
However, the results of different studies are linking the
lower tumor vascularity with poor outcomes and in
various other solid tumors [35]. Only recently acquired
knowledge has led to the conclusions that the local
tissue microenvironment contributes significantly to
tumor progression.
We hypothesize that a crosstalk exists between rectal
tumor cells and adjacent mucosa of distal margin.
Tumor secretes cytokines and other signaling proteins
which induce angiogenesis in the adjacent mucosa of
distal margin [34]. TGF-β1, a multifunctional cytokine,
has a complex role in angiogenesis. It is expressed in
number of cell types, including endothelial cells, de-
pending on the concentration, is both pro angiogenic
and antiangiogenic [36]. One molecule that may or-
chestrate this balance is endoglin [37]. Endoglin is an
auxiliary membrane receptor for transforming growth
factor beta (TGF-β) that modulates TGF-β signaling
[35]. Recently, endoglin has been identified as a key
regulator of tumor cells proliferation, migration, and
Fig. 6 Kaplan-Meier curves for recurrence-free survival according to CD105-MVD. a CD105-MVD in tumor (cut-off level of MVD 106.2/mm2). b
CD105-MVD in DRM (cut-off level of MVD 186.3 mm2). c CD105-MVD in PRM (cut-off level MVD 27.8/mm2
Table 5 Cox proportional-hazard regression analysis for tumor
recurrence (method “backward”)
Covariate p value OR (95 % CI)
Type of surgery (LAR versus APR) 0.0086 4.1103 1.4397–11.7346
Tumor size (≤4 versus >4 cm) 0.0577 0.3356 0.1093–1.0302
MVD in tumors (≤106.2 versus >106.2) 0.0385 0.3330 0.1182–0.9384
MVD in DRM (≤186.3 versus >186.3) 0.0537 2.9359 0.9885–8.7195
MVD in PRM (≤27.8 versus >27.8) 0.0218 0.2778 0.0935–0.8255
Overall model fit χ2 = 23.20, p = 0.0003
MVD microvessel density, OR odds ratio, 95 % CI confidence interval, DRM
distal resection margin, PRM proximal resection margin
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invasion [27, 35]. Craft et al. showed that endoglin ex-
pression was lost during prostate cancer cell progres-
sion, and that led to increased cell invasion and
migration [38]. It has been suggested that endoglin de-
ficiency results in angiogenic adaptation, weakens the
endothelial barrier, and increased metastatic spread and
may be associated with cancer progression [39].
Conclusions
In conclusion, this study showed that the CD105-MVD
is a useful marker for identifying patients with an ag-
gressive form of stage II RC. CD105-assessed MVD both
tumor and adjacent mucosa of distal resection margin
could help to identify patients with more aggressive dis-
ease and increased risk of developing tumor recurrence
after surgical treatment in the group of stage II RC.
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